Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDECRIN vs FUROSCIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Treatment of edema associated with congestive heart failure, cirrhosis, and renal disease,Treatment of hypertension (off-label),Treatment of ascites (off-label),Management of hypercalcemia (off-label)
Treatment of edema associated with congestive heart failure,Treatment of edema associated with cirrhosis of the liver,Treatment of edema associated with renal disease including nephrotic syndrome
Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
Terminal elimination half-life is 2-4 hours; prolonged in renal impairment (up to 30 hours) and in heart failure.
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (Cr Cl <30 m L/min) and 9-19 hours in anuria
Metabolized primarily in the liver, with approximately 30% excreted unchanged in urine and the remainder as metabolites, including the cysteine conjugate.
Furosemide is primarily metabolized by glucuronidation via UGT1A1, UGT1A9, and UGT2B7; to a lesser extent by cytochrome P450 enzymes.
Approximately 60-70% excreted unchanged in urine via glomerular filtration and tubular secretion; remaining 30-40% eliminated via biliary/fecal route.
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Approximately 95-98% bound, primarily to albumin.
91-99%, primarily to albumin
0.4-0.8 L/kg; reflects distribution primarily into extracellular fluid.
0.1-0.2 L/kg; higher in neonates (0.2-0.4 L/kg); restricted to extracellular fluid in adults
Oral: approximately 50-70% due to first-pass metabolism; Intravenous: 100%.
Subcutaneous: 99% compared to IV; oral: 60-70% (variable due to first-pass metabolism)
GFR 10-50 m L/min: 50% of normal dose. GFR <10 m L/min: not recommended or use with extreme caution.
e GFR 15-29 m L/min/1.73m2: 40 mg subcutaneously once daily. e GFR <15 m L/min: not recommended. e GFR ≥30: no adjustment needed.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A or B: no adjustment. Child-Pugh C: use with caution; reduce dose to 40 mg subcutaneously once daily. No specific pharmacokinetic data in severe impairment.
Oral: 1-3 mg/kg/day in 1-2 divided doses. IV: 1 mg/kg/dose, maximum 50 mg/dose.
Safety and efficacy not established in pediatric patients (<18 years). No approved dosing available.
Start at lowest dose (25-50 mg oral daily) due to increased risk of electrolyte disturbances and hypotension.
Start at 40 mg subcutaneously once daily. Monitor renal function and electrolyte levels closely. Consider lower doses due to age-related decreased renal function.
WARNING: EDECRIN is a potent diuretic which, if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule must be adjusted to the individual patient's needs.
Furosemide can cause profound diuresis with water and electrolyte depletion, leading to serious adverse events such as circulatory collapse and thromboembolic complications. Careful medical supervision is required.
Ototoxicity: Risk of hearing loss, especially with rapid IV administration or in patients with renal impairment; avoid concurrent use with other ototoxic drugs.,Volume and electrolyte depletion: Profound diuresis leading to dehydration, hypokalemia, hyponatremia, hypochloremia, and metabolic alkalosis.,Hypersensitivity reactions: Rash, eosinophilia, and anaphylaxis.,Gastrointestinal disturbances: Nausea, vomiting, diarrhea, and gastrointestinal bleeding (rare).,Hyperuricemia may precipitate gout.,Use with caution in patients with hepatic cirrhosis due to risk of hepatic encephalopathy.
Monitor for electrolyte disturbances (e.g., hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia),May cause ototoxicity, especially with rapid injection or high doses,Risk of renal impairment; monitor renal function,Can exacerbate systemic lupus erythematosus,Avoid in patients with known sulfonamide allergy
Anuria,Hypersensitivity to ethacrynic acid or any component of the formulation,Severe electrolyte depletion (e.g., hypokalemia, hyponatremia) until corrected,Concurrent use with other ototoxic agents (relative contraindication)
Anuria,Severe hypokalemia,Severe hyponatremia,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or pre-coma
Avoid excessive intake of high-sodium foods as they can counteract the diuretic effect. Grapefruit juice may increase the risk of ototoxicity; consumption should be limited. Alcohol can exacerbate hypotension and dehydration. Ensure adequate potassium intake through diet (e.g., bananas, oranges) unless directed otherwise by a healthcare provider.
Avoid foods high in sodium (e.g., processed meats, canned soups) to reduce fluid retention. No significant food-drug interactions. May increase potassium and magnesium loss; ensure adequate intake of potassium-rich foods (e.g., bananas, oranges) but monitor levels closely.
EDECRIN (ethacrynic acid) is classified as FDA Pregnancy Category B. Limited human data; animal studies have not demonstrated teratogenic effects. However, diuretic use during pregnancy may reduce placental perfusion. Fetal risks include electrolyte disturbances, volume depletion, and possible growth restriction. Use only if clearly needed.
Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause maternal hypovolemia, reduced placental perfusion, and fetal oligohydramnios; avoid if possible. Not associated with major congenital malformations.
It is not known if ethacrynic acid is excreted in human milk. Due to potential adverse effects in the nursing infant, such as electrolyte imbalance, caution is advised. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother. M/P ratio is unknown.
Furosemide is excreted into human breast milk in low amounts (M/P ratio approximately 0.2-0.5). Peak milk concentration ~0.4-0.6 µg/m L after 40 mg oral dose. Limited data suggest no adverse effects in breastfed infants. Use with caution, especially in neonates due to risk of diuresis and electrolyte imbalance.
Pregnancy may alter pharmacokinetics; however, no specific dose adjustments have been established. Use lowest effective dose and shortest duration. Monitor for hypovolemia and electrolyte imbalances, which may be more pronounced in pregnancy.
Furosemide pharmacokinetics may be altered in pregnancy due to increased volume of distribution and renal clearance. Lower doses may achieve desired diuresis; start at low end of dosing range (20-40 mg/day oral) and titrate based on clinical response and monitoring. Avoid high doses and prolonged use due to risk of hypovolemia and placental hypoperfusion.
EDECRIN (ethacrynic acid) is a potent loop diuretic that, unlike furosemide, is not a sulfonamide and can be used in patients with sulfonamide allergy. It can cause ototoxicity that is often irreversible, especially when given rapidly IV or with other ototoxic drugs like aminoglycosides. Monitor for hypokalemia, hypomagnesemia, and volume depletion. Use with caution in patients with hepatic cirrhosis due to risk of electrolyte-induced encephalopathy.
FUROSCIX (furosemide) is a subcutaneous loop diuretic for heart failure congestion. Onset of diuresis within 30 minutes; peak effect at 1-2 hours. Monitor for hypokalemia, hypomagnesemia, and ototoxicity. Use with caution in sulfonamide allergy. Avoid concurrent use with NSAIDs as they reduce diuretic efficacy.
Take this medication exactly as prescribed, usually once or twice daily.,Avoid alcohol and limit salt intake to reduce fluid retention.,Weigh yourself daily and report rapid weight gain or loss to your doctor.,Stand up slowly from sitting or lying down to prevent dizziness from low blood pressure.,Notify your doctor immediately if you experience hearing loss, ringing in the ears, or dizziness.,This drug may increase blood sugar; monitor if you have diabetes.,Avoid taking with other ototoxic medications like certain antibiotics without doctor approval.
Inject subcutaneously into the abdomen; rotate sites.,Take in the morning to avoid nocturia.,Monitor daily weight and report >2 lb/day gain.,Report hearing changes, ringing in ears, or dizziness.,Avoid excessive salt intake; limit alcohol.,Do not use with NSAIDs or lithium without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDECRIN vs FUROSCIX, answered by our medical review team.
EDECRIN is a Loop Diuretic that works by Ethacrynic acid inhibits the Na-K-Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to diuresis.. FUROSCIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDECRIN and FUROSCIX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDECRIN is: Oral: 50-100 mg once or twice daily, maximum 400 mg/day. IV: 50 mg (0.5 mg/kg) once, may repeat once at 2-hour intervals if needed.. The standard adult dose of FUROSCIX is: 80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDECRIN and FUROSCIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDECRIN is classified as Category C. EDECRIN (ethacrynic acid) is classified as FDA Pregnancy Category B. Limited human data; animal studies have not demonstrated teratogenic effects. However, diuretic use during preg. FUROSCIX is classified as Category C. Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.